| Gene symbol | ADGRE2 | Synonyms | CD312, CD97, EMR2, VBU | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19p13.12 | dbXrefs | |
| Description | adhesion G protein-coupled receptor E2 | ||||
| Gene symbol | CD33 | Synonyms | CD33rSiglec, SIGLEC-3, SIGLEC3, p67 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.41 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | CD33 molecule | ||||
| Gene symbol | COLEC10 | Synonyms | 3MC3, CL-10, CL-34, CLL1 | Type of gene | protein-coding |
| Chromosome | 8 | Map location | 8q24.12 | dbXrefs | |
| Description | collectin subfamily member 10 | ||||
| GTO ID | GTC1006 |
| Trial ID | ChiCTR2200061646 |
| Disease | Acute Myeloid Leukemia |
| Altered gene | CLL1|CD33|ADGRE2 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | ADGRE2/CD33/CLL1 CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Not Recruiting |
| Title | To evaluate the safety and efficacy of CLL1/CLL1+CD33/CD33/ADGRE2 CAR-T in the treatment of relapsed and refractory acute myeloid leukemia |
| Year | 2022 |
| Country | China |
| Company sponsor | The First Affiliated Hospital of Medical College of Zhejiang University |
| Cohort 1 | |||||||
|
|||||||